A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI-287 in Patients With Mild to Moderate Alzheimer's Disease
Latest Information Update: 07 Nov 2021
At a glance
- Drugs TPI 287 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 13 Apr 2020 Status changed from active, no longer recruiting to completed.
- 11 Nov 2019 Results assessing the safety, tolerability, and pharmacodynamics of the microtubule stabilizer TPI-287 (abeotaxane) in Alzheimer disease published in the JAMA Neurology
- 03 Apr 2019 Planned End Date changed from 1 Mar 2019 to 1 Nov 2019.